RxDoctor Payments Data

Hilda Zamani, DC

Family · Denton, TXNPI 1386733640

Payments from drug & device makers

$2,813in general payments, 2019–2025

Across 100 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$365
  • Novo Nordisk$272
  • Pfizer$216
  • Sanofi Pasteur Inc.$118
  • GSK$103
  • plus $614 from 16 others

What the payments were for

  • Food & beverage$2,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,813 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$9,828
Medicare patients
27
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$63,559
FarxigaDapagliflozin Propanediol51$53,361
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,574
EliquisApixaban12$7,023
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,373
Ventolin HfaAlbuterol Sulfate13$846
Gabapentin41$588
Omeprazole46$559
Lisinopril73$489
Atorvastatin Calcium77$466
Celecoxib13$373
Metformin Hcl66$351
Pantoprazole Sodium43$336
Rosuvastatin Calcium19$331
Losartan Potassium58$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$272$63,55958 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,125$61,93563 claims
PfizerEliquis$216$7,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →